Back
Full-text
Journal article

Validation of the International Tumor Budding Consensus Conference 2016 recommendations on tumor budding in stage I-IV colorectal cancer.

  • Dawson H Institute of Pathology, University of Bern, Bern, 3008 Switzerland. Electronic address: heather.dawson@pathology.unibe.ch.
  • Galuppini F Pathology Unit, Department of Medicine (DIMED), University of Padova, Padova, 35121 Italy.
  • Träger P Careanaesth AG, Zurich, 3006 Switzerland.
  • Berger MD Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, 3010 Switzerland.
  • Studer P Clinic of Visceral Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, 3010 Switzerland.
  • Brügger L Clinic of Visceral Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, 3010 Switzerland.
  • Zlobec I Institute of Pathology, University of Bern, Bern, 3008 Switzerland.
  • Inderbitzin D Department of General Surgery and Visceral Surgery, Bürgerspital Solothurn, Solothurn, 4500 Switzerland.
  • Lugli A Institute of Pathology, University of Bern, Bern, 3008 Switzerland.
Show more…
  • 2018-11-15
Published in:
  • Human pathology. - 2019
Colorectal cancer
Consensus conference
Prognostic factor
Tumor budding
Validation study
Adenocarcinoma
Aged
Colorectal Neoplasms
Disease-Free Survival
Female
Humans
Male
Neoplasm Staging
Prognosis
English Tumor budding is a robust prognostic parameter in colorectal cancer and can be used as an additional factor to guide patient management. Although backed by large bodies of data, a standardized scoring method is essential for integrating tumor budding in reporting protocols. The International Tumor Budding Consensus Conference (ITBCC) 2016 has proposed such a scoring system. The aim of this study is to validate the ITBCC method of tumor budding assessment on a well-characterized colorectal cancer cohort. Three hundred seventy-nine patients with resected stage I-IV colorectal cancer were entered into the study. Tumor budding was scored by 2 pathologists according to the ITBCC recommendations on hematoxylin and eosin-stained slides and scored as BD1 (low grade), BD2 (intermediate grade), and BD3 (high grade). Analysis was performed using a 3-tier approach, a 2-tier approach (BD1 + 2 versus BD3) and budding as a continuous variable. High-grade tumor budding was associated with adverse clinicopathological features including higher pT, higher pN stage, and higher TNM stage (all P < .001) and poorer overall survival on univariate analysis (P = .0251 for BD1/2/3, P = .0106 for BD1 + 2 versus BD3, and P = .0195 for continuous scores; hazard ratio, 1.023 [95% confidence interval, 1.004-1.043 per bud]). In stage II cancers, BD3 was associated with poorer disease-free survival (P < .01). Tumor budding assessed by the method proposed by the ITBCC is applicable to colorectal cancer resection specimens and can be used for widespread reporting in routine.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.ch/global/documents/169886
Statistics
Document views: 22 File downloads:
  • fulltext.pdf: 0